These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 7552742)
21. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics. Masuko S; Linhardt RJ Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937 [TBL] [Abstract][Full Text] [Related]
22. In vitro evaluation of synthetic heparin-like conjugates comprising different thrombin binding domains. Basten JE; Dreef-Tromp CM; de Wijs B; van Boeckel CA Bioorg Med Chem Lett; 1998 May; 8(10):1201-6. PubMed ID: 9871735 [TBL] [Abstract][Full Text] [Related]
23. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283 [TBL] [Abstract][Full Text] [Related]
24. Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III. Gan ZR; Li Y; Chen Z; Lewis SD; Shafer JA J Biol Chem; 1994 Jan; 269(2):1301-5. PubMed ID: 8288594 [TBL] [Abstract][Full Text] [Related]
25. A 2-sulfated, 3-linked alpha-L-galactan is an anticoagulant polysaccharide. Pereira MS; Vilela-Silva AC; Valente AP; Mourão PA Carbohydr Res; 2002 Nov; 337(21-23):2231-8. PubMed ID: 12433487 [TBL] [Abstract][Full Text] [Related]
27. The anticoagulant activation of antithrombin by heparin. Jin L; Abrahams JP; Skinner R; Petitou M; Pike RN; Carrell RW Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14683-8. PubMed ID: 9405673 [TBL] [Abstract][Full Text] [Related]
28. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371 [TBL] [Abstract][Full Text] [Related]
29. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide. Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564 [TBL] [Abstract][Full Text] [Related]
30. Monitoring of heparin and its low-molecular-weight analogs by silicon field effect. Milovic NM; Behr JR; Godin M; Hou CS; Payer KR; Chandrasekaran A; Russo PR; Sasisekharan R; Manalis SR Proc Natl Acad Sci U S A; 2006 Sep; 103(36):13374-9. PubMed ID: 16938875 [TBL] [Abstract][Full Text] [Related]
31. Heparin, carboxyl-reduced sulfated heparin, and Trestatin A sulfate. Antiproliferative and anticoagulant activities. Wessel HP; Hosang M; Tschopp TB; Weimann BJ Carbohydr Res; 1990 Sep; 204():131-9. PubMed ID: 2279243 [TBL] [Abstract][Full Text] [Related]
32. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. Yu G; LeBrun L; Gunay NS; Hoppensteadt D; Walenga JM; Fareed J; Linhardt RJ Thromb Res; 2000 Dec; 100(6):549-56. PubMed ID: 11152935 [TBL] [Abstract][Full Text] [Related]
33. Anticoagulant activity of artificial biomedical materials with co-immobilized antithrombin III and heparin. Miura Y; Aoyagi S; Ikeda F; Miyamoto K Biochimie; 1980; 62(8-9):595-601. PubMed ID: 7417594 [TBL] [Abstract][Full Text] [Related]
34. Sulfamate proton solvent exchange in heparin oligosaccharides: evidence for a persistent hydrogen bond in the antithrombin-binding pentasaccharide Arixtra. Langeslay DJ; Young RP; Beni S; Beecher CN; Mueller LJ; Larive CK Glycobiology; 2012 Sep; 22(9):1173-82. PubMed ID: 22593556 [TBL] [Abstract][Full Text] [Related]
35. Isolation of a pure octadecasaccharide with antithrombin activity from an ultra-low-molecular-weight heparin. Mourier PA; Guichard OY; Herman F; Viskov C Anal Biochem; 2014 May; 453():7-15. PubMed ID: 24561026 [TBL] [Abstract][Full Text] [Related]
36. Synthesis of heparin-like antithrombotics having perphosphorylated thrombin binding domains. Buijsman RC; Basten JE; Dreef-Tromp CM; van der Marel GA; van Boeckel CA; van Boom JH Bioorg Med Chem; 1999 Sep; 7(9):1881-90. PubMed ID: 10530936 [TBL] [Abstract][Full Text] [Related]
37. Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans? Pereira MS; Melo FR; Mourão PA Glycobiology; 2002 Oct; 12(10):573-80. PubMed ID: 12244069 [TBL] [Abstract][Full Text] [Related]
38. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021 [TBL] [Abstract][Full Text] [Related]
39. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma. Rezaie AR Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805 [TBL] [Abstract][Full Text] [Related]
40. Inhibitors of serine proteinases from blood coagulation cascade - view on current developments. Danalev D Mini Rev Med Chem; 2012 Jul; 12(8):721-30. PubMed ID: 22512557 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]